We are live on ! Find out more
INDP icon

Indaptus Therapeutics
INDP

13 hedge funds and large institutions have $1.57M invested in Indaptus Therapeutics in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

41% more capital invested

Capital invested by funds: $1.11M → $1.57M (+$459K)

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

0.01% less ownership

Funds ownership: 0.25% → 0.24% (-0.01%)

7% less funds holding

Funds holding: 14 → 13 (-1)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
13
Holders Change
-1
Holders Change %
-7.14%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
4
Reduced
4
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$10.3K
2
Renaissance Technologies
Renaissance Technologies
New York
+$8.65K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$946
4
Morgan Stanley
Morgan Stanley
New York
+$473

Top Sellers

Rank Fund Capital Flow
1
Northern Trust
Northern Trust
Illinois
-$24.7K
2
IHL
Investment House LLC
California
-$13.1K
3
TRCT
Tower Research Capital (TRC)
New York
-$6.35K
4
UBS Group
UBS Group
Switzerland
-$1.22K
5
PVI
Pine Valley Investments
New Jersey
-$405
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$691K +$946 +14 +0.2%
IHL
2
Investment House LLC
California
$283K -$13.1K -194 -5%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$149K +$10.3K +152 +8%
SAM
4
Strategy Asset Managers
California
$125K – – –
PVI
5
Pine Valley Investments
New Jersey
$122K -$405 -6 -0.4%
Renaissance Technologies
6
Renaissance Technologies
New York
$67K +$8.65K +128 +17%
VCM
7
Vivaldi Capital Management
Illinois
$66.1K – – –
State Street
8
State Street
Massachusetts
$53K – – –
TRCT
9
Tower Research Capital (TRC)
New York
$8.36K -$6.35K -94 -47%
Morgan Stanley
10
Morgan Stanley
New York
$2.83K +$473 +7 +23%
BSB
11
Bangor Savings Bank
Maine
$1.1K – – –
UBS Group
12
UBS Group
Switzerland
$377 -$1.22K -18 -78%
Wells Fargo
13
Wells Fargo
California
$281 – – –
Group One Trading
14
Group One Trading
Illinois
$19 – – –
JP Morgan Chase
15
JP Morgan Chase
New York
$19 – – –
Qube Research & Technologies (QRT)
16
Qube Research & Technologies (QRT)
United Kingdom
$3 – – –
Northern Trust
17
Northern Trust
Illinois
– -$24.7K -461 Closed

INDP Hedge Fund Activity: Q3 2023 in Review

13 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q3 2023, worth a combined $1.57M — up 41% from $1.11M a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of INDP and 0 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 4 added.

The largest buyer was Geode Capital Management, adding an estimated $10.3K. The largest seller was Northern Trust, exiting entirely with an estimated $24.7K sold.

  • 13 institutional investors held Indaptus Therapeutics (INDP) as of Q3 2023, down from 14 in Q2 2023.
  • Funds reported $1.57M of Indaptus Therapeutics stock for Q3 2023, up 41% quarter-over-quarter.
  • 0 funds opened new Indaptus Therapeutics positions in Q3 2023 and 1 closed out, a net change of -1 holder.
  • The largest Indaptus Therapeutics buyer in Q3 2023 was Geode Capital Management, an estimated $10.3K added.
  • The largest Indaptus Therapeutics seller in Q3 2023 was Northern Trust, an estimated $24.7K sold.

Based on aggregated 13F filings for Q3 2023.